Niagen Bioscience stock rises following positive clinical study

Published 09/06/2025, 13:58
© Reuters.

Investing.com -- Shares of Niagen Bioscience Inc (NASDAQ:NAGE) climbed 3.5% after the company announced results from a clinical study published in Aging Cell, which demonstrated the safety and efficacy of their patented nicotinamide riboside ingredient, Niagen®, in individuals with Werner syndrome (WS). The study marks the first of its kind to show such results in WS patients, a rare genetic disorder characterized by rapid aging.

The double-blind, placebo-controlled study revealed that daily supplementation with Niagen significantly raised blood NAD+ levels by about 140% and improved multiple clinical markers of cardiovascular and skin health in WS individuals. These findings are particularly noteworthy as WS, which affects 1 in 380,000 to 1 in 1,000,000 people globally, is caused by mutations that lead to accelerated cellular aging.

Niagen Bioscience’s focus on rare, age-related diseases has been further emphasized by the U.S. Food and Drug Administration’s (FDA) Orphan Drug Designation and Rare Pediatric Disease Designation for Niagen in treating Ataxia Telangiectasia (AT). This underscores the urgent need and potential value of Niagen in rare disease populations.

The clinical trial, which lasted 52 weeks, included a crossover with participants receiving either 1,000 mg/day of Niagen or a placebo for 26 weeks before switching treatments. The study not only showed a robust increase in NAD+ levels but also reported significant improvements in arterial stiffness and a cardioprotective lipid shift. Additionally, Niagen supported wound healing by reducing skin ulcer size, and no moderate or severe adverse events were reported, highlighting its clinical safety profile.

The positive outcomes of this study support further investigation into NAD+ augmentation as a therapeutic strategy in rare progeroid diseases and may indicate broader implications for healthier aging in the general population. The scientific community and investors alike are taking note of these developments, as reflected in the stock’s upward movement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.